John F Seymour

John F Seymour

UNVERIFIED PROFILE

Are you John F Seymour?   Register this Author

Register author
John F Seymour

John F Seymour

Publications by authors named "John F Seymour"

Are you John F Seymour?   Register this Author

100Publications

3941Reads

6Profile Views

Response in patients with -mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab.

Haematologica 2020 Jul;105(7):e382-e383

Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2020.253849DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327665PMC
July 2020

Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.

J Clin Oncol 2020 Jul 2:JCO1902192. Epub 2020 Jul 2.

Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.02192DOI Listing
July 2020

A predictive tool for early-stage CLL.

Blood 2020 May;135(21):1820-1821

Peter MacCallum Cancer Centre; University of Melbourne; The Royal Melbourne Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005426DOI Listing
May 2020

Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centre.

Support Care Cancer 2020 Apr 15. Epub 2020 Apr 15.

National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-020-05439-4DOI Listing
April 2020

Safety Is the Heart of the Matter.

Int J Radiat Oncol Biol Phys 2020 03 23;106(3):462-463. Epub 2019 Apr 23.

Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2019.02.022DOI Listing
March 2020

Abscopal Regressions of Lymphoma After Involved-Site Radiation Therapy Confirmed by Positron Emission Tomography.

Int J Radiat Oncol Biol Phys 2020 Mar 7. Epub 2020 Mar 7.

The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2020.02.636DOI Listing
March 2020

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma.

Br J Haematol 2019 09 24;186(6):e188-e191. Epub 2019 Jun 24.

Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16069DOI Listing
September 2019

Better Sepsis Management Rather Than Fluoroquinolone Prophylaxis for Patients With Cancer-Related Immunosuppression.

J Clin Oncol 2019 05 7;37(13):1139-1140. Epub 2019 Mar 7.

Monica A. Slavin, MD, Peter MacCallum Cancer Centre, and The National Centre for Infections in Cancer (NCIC), Melbourne, VIC, Australia; Leon J. Worth, PhD, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, and Doherty Institute, and The National Centre for Infections in Cancer (NCIC), Melbourne, VIC, Australia; John F. Seymour, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; and Karin A. Thursky, PhD, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, and Doherty Institute, and The National Centre for Infections in Cancer (NCIC), Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01474DOI Listing
May 2019

Outcome of patients with early-stage follicular lymphoma staged with F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone.

Eur J Nucl Med Mol Imaging 2019 01 7;46(1):80-86. Epub 2018 Aug 7.

Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4112-2DOI Listing
January 2019

Reply to M. Sorigue et al.

J Clin Oncol 2019 01 26;37(3):257-258. Epub 2018 Nov 26.

Michael MacManus, MD, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia; Richard Fisher, MD, PhD, and Bev McClure, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; and John F. Seymour, PhD, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, and Royal Melbourne Hospital, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.18.01309DOI Listing
January 2019

Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03.

J Clin Oncol 2018 10 5;36(29):2918-2925. Epub 2018 Jul 5.

Michael MacManus, Richard Fisher, Bev McClure, and John F. Seymour, Peter MacCallum Cancer Centre; Michael MacManus and John F. Seymour, University of Melbourne; Melbourne; Sidney Davis, The Alfred Hospital, Prahran, Victoria; Daniel Roos, The Royal Adelaide Hospital and The University of Adelaide, Adelaide, South Australia; Peter O'Brien, Genesis Cancer Care, Newcastle; Jayasingham Jayamohan, Westmead Hospital, Sydney, New South Wales; David Christie, Genesis Cancer Care, Tugun, Queensland; David Joseph, Sir Charles Gairdner Hospital Perth, Perth, Western Australia, Austrailia; Andrew Macann, Auckland City Hospital, Auckland, New Zealand; and Richard Tsang, Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.9892DOI Listing
October 2018

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

J Clin Oncol 2018 Oct 25:JCO1800359. Epub 2018 Oct 25.

Matthew S. Davids, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Gottfried von Keudell, Yale School of Medicine, New Haven, CT; Craig A. Portell, University of Virginia Health System, Charlottesville, VA; Jonathon B. Cohen, Winship Cancer Institute of Emory University, Atlanta, GA; David C. Fisher, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Francine Foss, Yale School of Medicine, New Haven, CT; Andrew W. Roberts, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia; John F. Seymour, Royal Melbourne Hospital, Peter MacCallum Cancer Centre, and University of Melbourne, Melbourne, Victoria, Australia; Rod A. Humerickhouse, AbbVie, Chicago, IL; and Constantine S. Tam, Royal Melbourne Hospital, Peter MacCallum Cancer Centre, St Vincent's Hospital, and University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00359
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00359DOI Listing
October 2018

Management of Pregnancy in Women With Chronic Myeloid Leukemia.

J Clin Oncol 2018 09 31;36(25):2657-2658. Epub 2018 May 31.

David M. Ross, Royal Adelaide Hospital, South Australian Health and Medical Research Institute, and Flinders University and Medical Centre, Adelaide, South Australia, Australia; Kate L. Burbury, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Andrew P. Grigg, Austin Hospital, Melbourne, Victoria, Australia; Timothy P. Hughes, Royal Adelaide Hospital and South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia; and John F. Seymour, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.6137DOI Listing
September 2018

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).

J Clin Oncol 2018 09 5;36(25):2593-2602. Epub 2018 Jul 5.

Qian Shi, Fang-Shu Ou, Jesse G. Dixon, and Thomas M. Habermann, Mayo Clinic, Rochester, MN; Norbert Schmitz, University of Muenster, Muenster; Michael Pfreundschuh, Universität des Saarlandes, Homburg; Marita Ziepert, University of Leipzig, Leipzig, Germany; David Cunningham, The Royal Marsden Hospital, Surrey, United Kingdom; John F. Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia; Ulrich Jaeger, Medical University of Vienna, Vienna, Austria; Corinne Haioun, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil; Hervé Tilly, Institut National de la Santé et de la Recherche Médicale U1245, Université de Rouen, Rouen; Hervé Ghesquieres and Bertrand Coiffier, Centre Hospitalier Lyon-Sud, Pierre-Benite; Raoul Herbrecht, Hôpital de Hautepierre, Strasbourg, France; Francesco Merli, Azienda Unità Sanitaria Locale-Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy; Jocelyne Flament, Celgene, Boudry, Switzerland; Tommy Fu, Celgene, Summit, NJ; and Christopher R. Flowers, Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.9124DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532366PMC
September 2018

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.

J Clin Oncol 2018 08 1;36(23):2395-2404. Epub 2018 Jun 1.

Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.8960DOI Listing
August 2018

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

J Clin Oncol 2018 07 1;36(19):1973-1980. Epub 2018 May 1.

Stephan Stilgenbauer and Johannes Bloehdorn, Ulm University, Ulm; Stephan Stilgenbauer, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; Barbara Eichhorst and Michael Hallek, Universitätsklinikum Köln, Köln; Johannes Schetelig, University Hospital, Technische Universität Dresden, Dresden; Clemens-Martin Wendtner, Klinikum Schwabing, Munich; Sebastian Böttcher, University Hospital of Schleswig-Holstein, Kiel, Germany; Peter Hillmen and Talha Munir, St James's University Hospital, Leeds; Anna Schuh, University of Oxford; Anna Schuh, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; John F. Seymour, Peter MacCallum Cancer Centre; John F. Seymour, University of Melbourne; Andrew W. Roberts, Royal Melbourne Hospital, Parkville, Victoria; Stephen P. Mulligan, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Steven Coutre, Stanford University Medical Center, Stanford, CA; Wojciech Jurczak, Jagiellonian University, Kraków, Poland; Sarit Assouline, McGill University, Montreal, Quebec, Canada; Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer Arzt, Su Young Kim, Maria Verdugo, and Gary Gordon, AbbVie, North Chicago, IL; Ahmed Hamed Salem, Ain Shams University, Cairo, Egypt; and William G. Wierda, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6840DOI Listing
July 2018

Venetoclax-Rituximab in Chronic Lymphocytic Leukemia.

N Engl J Med 2018 05;378(22):2143-2144

Academic Medical Center, Amsterdam, the Netherlands

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1805135DOI Listing
May 2018

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

N Engl J Med 2018 Mar;378(12):1107-1120

From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) - all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) - both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne-Bonn, Cologne, Germany (B.E.); St. James's University Hospital, Leeds (P.H.), and F. Hoffmann-La Roche, Welwyn Garden City (M.B., K.H.) - both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) - all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1713976DOI Listing
March 2018

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

N Engl J Med 2018 03;378(13):1211-1223

From the Peter MacCallum Cancer Centre, Melbourne, VIC (C.S.T., M.A.A., R.A., S.H., R.J.H., K.B., G.T., J.D.I., M.B., D.W., S.L., S.-J.D., M.A.D., J.F.S., A.W.R.), and the Victorian Comprehensive Cancer Centre (C.S.T., M.A.A., R.A., S.H., R.J.H., K.B., D.W., S.-J.D., M.A.D., J.F.S., A.W.R.), the Faculty of Medicine (C.S.T., R.J.H., S.-J.D., M.A.D., J.F.S., A.W.R.) and Centre for Cancer Research (S.-J.D., M.A.D.), University of Melbourne, the Department of Clinical Haematology and Bone Marrow Transplantation, the Royal Melbourne Hospital (C.S.T., M.A.A., K.B., J.F.S., A.W.R.), and the Division of Cancer and Haematology, Walter and Eliza Hall Institute of Medical Research (M.A.A., A.W.R.), Parkville, VIC - all in Australia; and the University Hospital of Schleswig-Holstein, Kiel (C.P.), and Klinikum der Universität, Ludwig-Maximilian University of Munich, Munich (M.D.) - both in Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1715519DOI Listing
March 2018

Patient perceptions of treatment-free remission in chronic myeloid leukemia.

Leuk Lymphoma 2018 02 15;59(2):406-415. Epub 2017 Jun 15.

d Haematology Directorate, SA Pathology , Flinders University and Medical Centre , Adelaide , SA , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1337114DOI Listing
February 2018

Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015.

Hematol Oncol 2017 Dec 4;35(4):397-407. Epub 2017 Apr 4.

Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2411DOI Listing
December 2017

Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.

Leuk Lymphoma 2017 12 15;58(12):2811-2814. Epub 2017 May 15.

a Department of Hematology , St Vincent's Hospital , Melbourne , Australia.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2017.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2017.1315115DOI Listing
December 2017

Obinutuzumab Treatment of Follicular Lymphoma.

N Engl J Med 2017 12;377(26):2605-2606

Ludwig-Maximilians-University Hospital, Munich, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1714337#SA2DOI Listing
December 2017

Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes.

Leuk Lymphoma 2017 Oct 28;58(10):2379-2386. Epub 2017 Feb 28.

a Department of Infectious Diseases , Peter MacCallum Cancer Centre , East Melbourne , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1295141DOI Listing
October 2017

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.

N Engl J Med 2017 10;377(14):1331-1344

From King's College Hospital (R.M.) and the Cancer Research UK and University College London Cancer Trials Centre (E.P., W.T.), London, and the Cancer Research UK Centre, University of Southampton, Southampton (A.D.) - all in the United Kingdom; the Tokai University School of Medicine, Isehara, Japan (K.A.); the University of Kiel, Kiel (W.K.), Gemeinschaftspraxis, Würzburg (R. Schlag), HELIOS Klinikum Erfurt, Erfurt (M.H.), and the Ludwig-Maximilians-University Hospital Grosshadern, Munich (W.H.) - all in Germany; Monash Health and Monash University (S.O.) and the Peter MacCallum Cancer Centre and University of Melbourne (J.F.S.), Melbourne, VIC, Australia; Foothills Medical Centre and Tom Baker Cancer Centre, Calgary, AB (C.O.), and the Cross Cancer Institute, Edmonton, AB (R. Sangha) - both in Canada; Charles University, Prague, Czech Republic (M.T.); and F. Hoffmann-La Roche, Basel, Switzerland (M.W., G.F.-R., K.R., T.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1614598DOI Listing
October 2017

High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma.

Br J Haematol 2017 09 29;178(6):991-994. Epub 2016 Jul 29.

Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14187DOI Listing
September 2017

Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.

Clin Cancer Res 2017 Aug 18;23(16):4527-4533. Epub 2017 Jan 18.

Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0955DOI Listing
August 2017

Azacitidine in adult patients with acute myeloid leukemia.

Crit Rev Oncol Hematol 2017 Aug 3;116:159-177. Epub 2017 Jun 3.

Hôpital Saint Louis, Institut Universitaire d'Hématologie, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2017.05.010DOI Listing
August 2017

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.

Blood 2017 06 4;129(25):3362-3370. Epub 2017 May 4.

Department of Clinical Haematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Parkville, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-01-763003DOI Listing
June 2017

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.

J Clin Oncol 2017 May 3;35(15):1678-1685. Epub 2017 Apr 3.

Kenneth F. Bradstock and Warwick Benson, Westmead Hospital, University of Sydney; Arno Enno, Sandra Deveridge, and Philip Rowlings, Calvary Mater Newcastle Hospital, Newcastle; Luke Coyle, Royal North Shore Hospital, St Leonards; Campbell Tiley, Central Coast Health, Gosford; John Moore, St Vincent's Hospital; Mark Hertzberg, Prince of Wales Hospital, Sydney; Kimberly Cartwright, Wollongong Hospital, Wollongong; Ilona Cunningham, Concord Repatriation General Hospital, Concord; John Taper, Nepean Hospital, Penrith, New South Wales; Emma Link, Juliana Di Iulio, and John F. Seymour, Peter MacCallum Cancer Centre; Jeff Szer, Andrew Grigg, Andrew W. Roberts, and John F. Seymour, University of Melbourne; Andrew H. Wei, Monash University; Anthony Schwarer, Box Hill Hospital; Lynda Campbell, Victorian Cancer Cytogenetics Service, Melbourne; Jeff Szer, Andrew Grigg, and Andrew W. Roberts, Royal Melbourne Hospital, Parkville; Phillip Campbell, Deakin University School of Medicine, Geelong, Victoria; Paula Marlton, Anthony K. Mills, and Devinder Gill, University of Queensland, Brisbane, Queensland; Ray M. Lowenthal, University of Tasmania, Hobart, Tasmania; Ian D. Lewis and Peter Bardy, Royal Adelaide Hospital; Uwe Hahn, Queen Elizabeth Hospital, Adelaide, South Australia; James D'Rozario, The Canberra Hospital, Garran, Canberra, Australia Capital Territory; Gavin Cull, Sir Charles Gairdner Hospital; Michael F. Leahy, University of Western Australia; and Paul Cannell, Royal Perth Hospital, Perth, Western Australia, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.70.6374
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.70.6374DOI Listing
May 2017

Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors.

Br J Haematol 2017 04 15;177(2):324-328. Epub 2016 May 15.

Department of Haematology, Peter MacCallum Cancer Centre, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14062DOI Listing
April 2017

The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.

Eur J Cancer 2017 04 23;75:195-203. Epub 2017 Feb 23.

Department of Haematology, Peter MacCallum Cancer Centre and University of Melbourne, 305 Grattan Street, Melbourne VIC 3000, Australia; Department of Hematology, Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Hospital Ave, Nedlands WA 6009, Australia; University of Western Australia, 35 Stirling Hwy, Crawley, WA 6009, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.12.029DOI Listing
April 2017

Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.

Br J Haematol 2017 03 25;176(5):829-831. Epub 2016 Feb 25.

Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14000DOI Listing
March 2017

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

J Clin Oncol 2017 Mar 17;35(8):826-833. Epub 2017 Jan 17.

Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Andrew W. Roberts, John F. Seymour, and Mary Ann Anderson, University of Melbourne; Andrew W. Roberts and Mary Ann Anderson, Royal Melbourne Hospital and Eliza Hall Institute of Medical Research; and John F. Seymour, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; John M. Pagel, Swedish Cancer Institute, Seattle, WA; Brad S. Kahl, Washington University Medical School, St Louis, MO; William G. Wierda, University of Texas MD Anderson Cancer Center, Houston, TX; Soham Puvvada, University of Arizona, Tucson, AZ; Thomas J. Kipps, University of California San Diego, San Diego, CA; Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Jeremy A. Ross, Lori Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod A. Humerickhouse, and Gary B. Gordon, AbbVie, Chicago, IL; Ahmed Hamed Salem, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; Franklin Peale, Genentech, South San Francisco, CA; John F. Gerecitano, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.4320DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455685PMC
March 2017

When to treat patients with relapsed follicular lymphoma.

Expert Rev Hematol 2017 Mar 15;10(3):187-191. Epub 2017 Feb 15.

c Department of Haematology , Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre , Parkville , VIC , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1291339DOI Listing
March 2017

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Lancet Oncol 2017 Feb 13;18(2):230-240. Epub 2017 Jan 13.

Victorian Comprehensive Cancer Centre, Parkville, Melbourne, VIC, Australia; Faculty of Medicine, University of Melbourne, Parkville, Melbourne, VIC, Australia; Department of Clinical Haematology and BMT, The Royal Melbourne Hospital, Parkville, Melbourne, VIC, Australia; Division of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30012-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316338PMC
February 2017

Transformed Lymphoma.

Hematol Oncol Clin North Am 2016 Dec;30(6):1317-1332

Department of Haematology, Peter MacCallum Cancer Centre, Parkville 3050, Australia; Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2016.07.012DOI Listing
December 2016

Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia.

Authors:
John F Seymour

Ann Hematol 2016 Aug 14;95(8):1361-2. Epub 2016 May 14.

Peter MacCallum Cancer Centre, St Andrews Place East Melbourne, Melbourne, Victoria, 3002, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-016-2695-xDOI Listing
August 2016

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

Blood 2016 06 11;127(25):3215-24. Epub 2016 Apr 11.

Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia; Department of Clinical Hematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Parkville, VIC, Australia;

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2016-01-68
Publisher Site
http://dx.doi.org/10.1182/blood-2016-01-688796DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920022PMC
June 2016

New Agents to Treat Chronic Lymphocytic Leukemia.

N Engl J Med 2016 06;374(22):2186-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1602674DOI Listing
June 2016

Stage I-II follicular lymphoma: an endangered species?

Leuk Lymphoma 2015 23;56(8):2229-30. Epub 2015 Sep 23.

b Department of Haematology , Peter MacCallum Cancer Centre , East Melbourne , VIC , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1083737DOI Listing
April 2016

Mantle Cell Lymphoma.

J Clin Oncol 2016 Apr 11;34(11):1256-69. Epub 2016 Jan 11.

Chan Yoon Cheah, Sir Charles Gairdner Hospital and PathWest Laboratory Medicine WA, Nedlands; Chan Yoon Cheah, University of Western Australia, Crawley, Western Australia; John F. Seymour, Peter MacCallum Cancer Centre, East Melbourne; John F. Seymour, University of Melbourne, Parkville, Victoria, Australia; and Chan Yoon Cheah and Michael L. Wang, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.5904DOI Listing
April 2016

Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.

Semin Oncol 2016 Apr 6;43(2):274-9. Epub 2016 Feb 6.

University of Melbourne, Parkville, Victoria, Australia; Department of Clinical Haematology and BMT, Royal Melbourne Hospital, Parkville, Victoria, Australia; Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.02.014DOI Listing
April 2016

Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit.

J Antimicrob Chemother 2016 Feb 30;71(2):497-505. Epub 2015 Oct 30.

Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia

View Article

Download full-text PDF

Source
http://jac.oxfordjournals.org/content/early/2015/10/29/jac.d
Web Search
http://www.jac.oxfordjournals.org/lookup/doi/10.1093/jac/dkv
Publisher Site
http://dx.doi.org/10.1093/jac/dkv343DOI Listing
February 2016

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Blood 2016 Jan 20;127(2):208-15. Epub 2015 Oct 20.

Department I for Internal Medicine and Center of Integrated Oncology, University of Cologne, Cologne, Germany; Cluster of Excellence Cellular Stress Responses in Aging Associated Diseases, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-06-651125DOI Listing
January 2016

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

N Engl J Med 2016 Jan 6;374(4):311-22. Epub 2015 Dec 6.

From the Department of Clinical Haematology and the Bone Marrow Transplantation Unit, Royal Melbourne Hospital (A.W.R., M.A.A.), the Division of Cancer and Haematology, Walter and Eliza Hall Institute of Medical Research (A.W.R., M.A.A.), and the Victorian Comprehensive Cancer Centre (A.W.R., J.F.S.), Parkville, VIC, and the University of Melbourne (A.W.R., J.F.S.) and Peter MacCallum Cancer Centre (J.F.S.), Melbourne, VIC - all in Australia; Dana-Farber Cancer Institute, Boston (M.S.D., J.R.B.); the Swedish Medical Center, Seattle (J.M.P.); Washington University, St. Louis (B.S.K.); University of Arizona, Tucson (S.D.P.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.F.G.); University of California, San Diego, San Diego (T.J.K.); AbbVie, North Chicago, IL (L.G., S.W., M.D., M.Z., M.B.D., E.C., S.H.E., R.A.H.); and University of Texas M.D. Anderson Cancer Center, Houston (W.G.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1513257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7107002PMC
January 2016

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.

Lancet Haematol 2015 Oct 1;2(10):e445-55. Epub 2015 Oct 1.

University of Queensland Diamantina Institute, Translational Research Institute, University of Queensland, Brisbane, QLD, Australia; Princess Alexandra Hospital, Brisbane, QLD, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(15)00150-7DOI Listing
October 2015

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.

Lancet Haematol 2015 Apr 25;2(4):e166-74. Epub 2015 Mar 25.

Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Melbourne, VIC, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(15)00026-5DOI Listing
April 2015